- Discovery Pharmacology 1 and 2 will be reorganized into Specialty Discovery Pharmacology Dept. and Oncology Discovery Pharmacology Dept., effective July 1, 2026.
- Hiroyasu Muramatsu appointed Head of Specialty Discovery Pharmacology Dept. and Kenji Kashima appointed Head of Oncology Discovery Pharmacology Dept., effective July 1, 2026.
- Yasuhiro Saito appointed Head of Quality & Regulatory Compliance Strategy Dept., effective July 1, 2026.
- Atsushi Yamaga appointed Head of Oncology Marketing Dept., effective July 1, 2026.
Organizational changes
Discovery Pharmacology 1 Dept. and Discovery Pharmacology 2 Dept. will be reorganized and renamed as Specialty Discovery Pharmacology Dept. and Oncology Discovery Pharmacology Dept., effective July 1, 2026; the change aims to strengthen pharmacology capabilities, enhance organizational effectiveness, integrate drug discovery technologies across therapeutic areas, streamline the R&D framework and accelerate the transition from scientific outcomes to clinical proof of concept.
Personnel changes
Effective July 1, 2026: Hiroyasu Muramatsu appointed Head of Specialty Discovery Pharmacology Dept., previously Deputy Head (Specialty 1) of Discovery Pharmacology 1 Dept.; Kenji Kashima appointed Head of Oncology Discovery Pharmacology Dept., previously Deputy Head (Oncology 1) of Discovery Pharmacology 1 Dept.; Yasuhiro Saito appointed Head of Quality & Regulatory Compliance Strategy Dept., previously Head of Quality Assurance Dept.; Atsushi Yamaga appointed Head of Oncology Marketing Dept., previously Deputy Head (Product Strategy) of Oncology Marketing Dept.
